Phase 1 primary completion: A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Sponsor: Nested Therapeutics, Inc. Status: Recruiting. Conditions: Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation. NCT06326411.